The Miami Entrepreneur

The War Over Cheaper Ozempic Won’t End Well for Some Investors

Read Time:9 Second

Once Eli Lilly and Novo Nordisk increase the supply of weight-loss medications, companies such as Hims & Hers may find it trickier to sell compounded versions of the drugs.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post Smidge (SMIDGE) price plunge makes investors to turn to Solciety (SLCTY) for gains
Next post YouTube dominates streaming, forcing media companies to decide whether it’s friend or foe